6
Casꢁllo Warnken V y cols. Comparación entre pacientes operados por cáncer colorrectal (división 50 años). Rev Argent Cir. 2026;118(1):e-1910
The literature demonstrates a tendency to
■
TABLE 4
associate young paꢁents with more advanced clinical
Comparison of treatments, recurrence and mortality by group
3
stages at the ꢁme of diagnosis . As an example, a
retrospecꢁve study demonstrated that the cohort
of older adults exhibited lower rates of stages III-IV
compared to the younger paꢁent populaꢁon (46.4%
Group 1
n (%)
Group 2
n (%)
p-value
Neoadjuvant therapy (rectum)
Global adjuvant therapy
Stage II
3 (50)
17 (53.1)
3 (30)
8 (50)
47 (44.3)
6 (15)
1
1
5
vs. 69.3%) . In our cohort, the results are contrary,
although there are no significant differences. It worth
noꢁng that the overall proporꢁon of stage IV paꢁents in
our sample is low, which may be due to selecꢁon bias.
This is because, in cases of metastasis, iniꢁal therapy is
typically systemic rather than surgical.
0.382
0.358*
0.407
1*
Recurrence
5 (21.7)
1 (4.6)
11 (14.5)
(4) 5.6
Overall mortality
*
Fisher’s exact test. Pearson’s chi-square test was performed in the rest
Regarding the analysis of the surgical
of the analyses.
specimen, large databases such as SEER (Surveillance,
Epidemiology, and End Results) show a higher number
of poorly differenꢁated adenocarcinomas with signet
ring cells, especially in paꢁents < 40 years. This would
translate into the presence of more aggressive tumors
with worse oncological outcomes1 . In our series,
the histological examinaꢁon revealed a higher rate of
poorly differenꢁated tumors in younger paꢁents. While
there were no significant differences, this result aligns
with the exisꢁng literature.
Discussion
This is the first Chilean study to compare the
0,16
characterisꢁcs of paꢁents ≤ 50 years old versus > 50
years who underwent surgery for CRC. This is a response
to the mounꢁng concern regarding the comprehension
of this neoplasm’s behavior across different age ranges.
In recent decades, the incidence of colorectal cancer
has increased among paꢁents < 50 years, a group
that has not tradiꢁonally been included in screening
programs. These cases generally present clinical and
histopathological characterisꢁcs that differ from those
observed in older paꢁents, as well as a different disease
progression. Addiꢁonally, cancer stage tends to be more
advanced at the ꢁme of diagnosis, and the disease can
Finally, regarding postoperaꢁve treatment,
several studies have shown that young paꢁents are
2
to 4 ꢁmes more likely to receive systemic therapy
for the same clinical stages, especially in stage II,
where chemotherapy is not the standard treatment.
Addiꢁonally, paꢁents < 50 years are more likely to be
overtreated with more aggressive regimens without
1
7
3
clear evidence of their usefulness . This is consistent
with our results, as adjuvant therapy was used in 53.1%
of the younger populaꢁon compared with 44.3% of
the older populaꢁon. When we compare the subgroup
of stage II paꢁents, we see that younger paꢁents are
twice as likely to receive postoperaꢁve chemotherapy
as older paꢁents (30% vs. 15%). Despite the apparent
important difference, it was not staꢁsꢁcally significant
be more aggressive .
In recent years, there has been an increase
in the number of studies on these phenomena, as
evidenced by the growing body of literature on the
subject. Firstly, it has been noted that young paꢁents,
who are not typically included in screening groups, oꢃen
receive late diagnoses . A retrospecꢁve cohort study
published in 2021 confirms that 55.3% of colonoscopies
performed on paꢁents aged 50 to 54 years were
requested for screening purposes, as opposed to only
1
0
(
p = 0.358).
The strength of this study lies in its ability to
provide valuable informaꢁon by idenꢁfying different
demographic, clinical, anatomical, histopathological,
and therapeuꢁc paꢂerns in both groups. This
allows the findings to be contextualized within the
current literature and provides evidence from a local
perspecꢁve. The main limitaꢁons of our study include
the small sample size and its retrospecꢁve design.
Addiꢁonally, the absence of geneꢁc and molecular
data hinders a comprehensive characterizaꢁon. In
this regard, it is imperaꢁve to underscore the ongoing
collaboraꢁve effort to analyze molecular and geneꢁc
markers in paꢁents undergoing surgery for CRC. We
also hope to be able to report these results in a future
publicaꢁon.
1
4
9.7% of those performed on paꢁents between 40 and
11
9 years . In this group, the primary indicaꢁon was
the presence of anemia or gastrointesꢁnal bleeding
in 31.6% of cases. Consequently, several insꢁtuꢁons,
including the American Cancer Society, and the US
Prevenꢁve Services Task Force, among others, are
proposing to lower the screening age to 45 years .
From a demographic perspecꢁve, men were
overrepresented in group 1 (p = 0.016). This trend has
also been described in the internaꢁonal literature .
Conversely, younger paꢁents exhibited a lower
prevalence of comorbidiꢁes, as evidenced by a higher
proporꢁon of cases classified as ASA grade 1 in group 1.
This difference was staꢁsꢁcally significant (p = 0.004).
Similarly, group 1 exhibited a higher proporꢁon
1
2
1
3
In conclusion, in CCR paꢁents aged 50 years
or younger, the disease manifested with greater
frequency in males, exhibiꢁng a reduced prevalence
of comorbidiꢁes and elevated rates of rectal cancer.
of rectal cancer, aligning with prior studies indicaꢁng
that young paꢁents are 70% more likely to have leꢃ-
sided colon and rectal tumors
5
,14
.